Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
São Paulo - Delayed Quote BRL

Zoetis Inc. (Z1TS34.SA)

Compare
57.00
+1.20
+(2.15%)
At close: February 21 at 3:35:26 PM GMT-3

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in BRL.
NameTitlePayExercisedYear Born
Ms. Kristin C. Peck CEO & Director 20.18M 29.67M 1971
Mr. Wetteny N. Joseph CPA Executive VP & CFO 9.12M -- 1972
Dr. Robert J. Polzer Ph.D. Executive VP and President of Research & Development 6.71M 308.76k 1970
Mr. Keith Sarbaugh Executive VP & Chief Digital and Technology Officer -- -- 1979
Mr. Steven Frank Vice President of Investor Relations -- -- --
Ms. Roxanne Lagano Executive VP, General Counsel & Corporate Secretary -- -- 1965
Ms. Julie A. Fuller Executive VP, Chief Human Resources Officer & Global Operations -- -- 1973
Ms. Jeannette Ferran Astorga Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer -- -- 1976
Mr. Nick Ashton Executive VP and President of Global Manufacturing & Supply -- -- 1973
Mr. Jamie Brannan Executive VP & Chief Commercial Officer -- -- 1973

Zoetis Inc.

10 Sylvan Way
Parsippany, NJ 07054
United States
973 822 7000 https://www.zoetis.com
Sector: 
Healthcare
Full Time Employees: 
13,800

Description

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.

Corporate Governance

Zoetis Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 16, 2025 at 12:00 AM UTC

Ex-Dividend Date

April 30, 2025 at 12:30 PM UTC - May 5, 2025 at 12:30 PM UTC

Zoetis Inc. Earnings Date

Recent Events